<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.20.1 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-05-09T13:18:52Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:amrn="http://www.amarincorp.com/20130331" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="amrn-20130331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <amrn:DebtInstrumentRedemptionPrice contextRef="eol_PE46938---1310-Q0003_STD_0_20120131_0" unitRef="pure" decimals="2" id="id_1522721_AE0BD84D-676A-43A8-B8F2-277D885B107F_1_0">1.00</amrn:DebtInstrumentRedemptionPrice>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1310-Q0003_STD_0_20120131_0_500478x514203" unitRef="pure" decimals="3" id="id_1522721_D10C2F85-5125-4F16-A828-FD97124C23C8_1002_1">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20120131_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D10C2F85-5125-4F16-A828-FD97124C23C8_1002_0">150000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1310-Q0003_STD_0_20120131_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_1003_1">150000000</us-gaap:DebtInstrumentFairValue>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130502_0_513696x531187" unitRef="shares" decimals="INF" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1002_500006">371108</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130502_0_513696x536012" unitRef="shares" decimals="INF" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_2002_500008">150312023</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0003_STD_0_20130328_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_645AB998-988C-4445-BAD6-69B812D2EED2_2002_1">7.41</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0003_STD_0_20130328_0_507189x517783" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_645AB998-988C-4445-BAD6-69B812D2EED2_3002_0">8.15</us-gaap:SharePrice>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20120726_0_530648x536635" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_1004_2">11600000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_507611x504721_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_7672B5B2-089A-4A59-9CCF-ACA22860E609_2003_1">900000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750" unitRef="shares" decimals="1" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_3002_7">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_3002_8">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_3002_6">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750_513651x509432" unitRef="shares" decimals="1" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_4002_13">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750_513651x509432" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_4002_14">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750_513651x509432" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_4002_12">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_5002_15">35200000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1310-Q0003_STD_0_20091016_0_512768x517750_513651x509432" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_2002_11">0.90</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3006_900020">-64414000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2002_35">245822000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_3004_5">191387000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3001_500020">113790000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3001_400020">136427695</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x502884" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3004_700020">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3005_800020">-656744000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_3003_600020">478757000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20120331_0_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_3001_5">191387000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_6">937000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDF28B68-D96E-424E-A52C-0E4AE050C8F0_1_1">15600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_34">625086000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:PurchaseObligation contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_422BA526-221E-40C8-BA4E-0D5E76363572_1_0">5400000</us-gaap:PurchaseObligation>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDF28B68-D96E-424E-A52C-0E4AE050C8F0_1_0">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_7">7051000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_1_1">9735000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_11">5335000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_38">-60086000</us-gaap:StockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_12">11193000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_1_0">6211000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_28" />
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_3">1400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_33">150671802</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_23">137735000</us-gaap:SeniorLongTermNotes>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_2AF3E99B-7B48-427C-9677-4F7111E4E41D_1_0">9866826</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_27">331417000</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_16">22945000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_18">2865000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_26">807000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_10">11993000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_37">-809801000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_13">271331000</us-gaap:Assets>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_4">3441000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_5">27435000</us-gaap:InventoryNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_39">271331000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_3005_4">1455000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_2">201780000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_80A505D0-5D7A-4351-8461-8784BF747793_1001_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_32">150691881</us-gaap:CommonStockSharesIssued>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_20">42391000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_1_3">1422000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_1_2">10067000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_30">124846000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_GBP_per_shares" decimals="2" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_3001_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_17">4646000</us-gaap:InterestPayableCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_80A505D0-5D7A-4351-8461-8784BF747793_1001_1">431000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_8">242044000</us-gaap:AssetsCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_3004_5">65359000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_2AF3E99B-7B48-427C-9677-4F7111E4E41D_1_1">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_19">11935000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_9">766000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1_24">85873000</us-gaap:LongTermDebtNoncurrent>
  <amrn:ExcessFairValueOverPrincipalValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_820C70CE-6BD5-4381-BB6F-6B15E7587F36_3_4">23900000</amrn:ExcessFairValueOverPrincipalValue>
  <amrn:CashDiscountPercent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0" unitRef="pure" decimals="2" id="id_1522721_0A132215-A454-4BF7-95CB-40C51624E25E_1001_0">0.02</amrn:CashDiscountPercent>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_1_4">15600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_1_1">41400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_1_5">700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_1_3">49000000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x507364" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_4_4">15600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x507364" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_4_5">700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x507364" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_4_3">49000000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x508799" unitRef="iso4217_USD" decimals="-5" id="id_1522721_83A44460-4195-48F5-9D23-A51FCAD34320_2_1">41400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_3001_1">2100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_3001_2">137700000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_1002_1">126200000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_3001_7">1100000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203_507189x531855" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_3001_4">10200000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517820" unitRef="shares" decimals="INF" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1001_1">17500</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517820" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1001_2">17.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517820" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1001_3">1/17/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517821" unitRef="shares" decimals="INF" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1002_1">1734888</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517821" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1002_2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517821" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1002_3">7/30/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517822" unitRef="shares" decimals="INF" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1003_1">7487388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517822" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1003_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517822" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1003_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517823" unitRef="shares" decimals="INF" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1004_1">627050</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517823" unitRef="iso4217_USD_per_Right" decimals="2" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1004_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517823" id="id_1522721_A2543771-3EC4-4EB8-8733-2C43115C8183_1004_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_504957x514053_507189x517789_530648x536635" unitRef="iso4217_GBP" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_2002_6">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_504957x514053_507189x517789_530648x536635" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_2001_6">15200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_504957x514053_509379x517760_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_E0022012-FCE5-4BC5-A7E9-C31EE256A1AB_1001_0">36100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_7001_500009">124846000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_7001_400009">150691881</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x502884" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_7004_700009">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_7005_800009">-809801000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_7003_600009">625086000</us-gaap:StockholdersEquity>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x502651" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_3003_4">72000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x509157" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_3001_4">507000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x586139" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_3002_4">256000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x589068" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_3004_4">620000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517786" unitRef="iso4217_GBP" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_3002_0">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517786" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_3001_0">11400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517787" unitRef="iso4217_GBP" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_4002_1">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517787" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_4001_1">11400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517786" unitRef="iso4217_GBP" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_5002_4">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517786" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_5001_4">7600000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517787" unitRef="iso4217_GBP" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_6002_5">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517787" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_6001_5">7600000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_507611x504721_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_7672B5B2-089A-4A59-9CCF-ACA22860E609_2001_2">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x511672" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_3003_5">748000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ForeignCurrencyDerivativesAtFairValueNet contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x512835" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDE90AE0-565D-4FD5-AFE1-8303D769F646_2001_1">700000</us-gaap:ForeignCurrencyDerivativesAtFairValueNet>
  <us-gaap:NotionalAmountOfForeignCurrencyDerivatives contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x512835" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDE90AE0-565D-4FD5-AFE1-8303D769F646_2001_0">15000000</us-gaap:NotionalAmountOfForeignCurrencyDerivatives>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x513730" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_3004_2">15600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x513730" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_3002_5">15600000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_3001_5">49011000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_509379x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_2001_0">49011000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_509379x517760_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_5003_16">7500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_511531x506189" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1001_25">15600000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20130331_0_511531x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2001_22">49011000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1006_900010">-5962000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_3001_34">116602000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_1004_1">123125000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1001_500010">113321000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1001_400010">135832542</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x502884" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1004_700010">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1005_800010">-568459000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_1003_600010">449393000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20111231_0_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_1001_1">123125000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_6">937000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_34">619266000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_7">3253000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_2_1">15471000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_11">4951000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_38">-3997000</us-gaap:StockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_12">11355000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_2_0">5465000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_28" />
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_33">150340854</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_23">134250000</us-gaap:SeniorLongTermNotes>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_27">314852000</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_16">17458000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_26">816000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_10">8044000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_37">-747643000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_13">310855000</us-gaap:Assets>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_5">21262000</us-gaap:InventoryNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_39">310855000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_2">260242000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_80A505D0-5D7A-4351-8461-8784BF747793_1002_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_32">150360933</us-gaap:CommonStockSharesIssued>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_20">25202000</us-gaap:LiabilitiesCurrent>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_83284606-A744-4253-AE59-CD618835028F_2_2">326000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_30">124597000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_GBP_per_shares" decimals="2" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_3002_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_17">2520000</us-gaap:InterestPayableCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_80A505D0-5D7A-4351-8461-8784BF747793_1002_1">269000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_8">285694000</us-gaap:AssetsCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_1004_1">69430000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_19">5224000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_9">811000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2_24">85153000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_1_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_1_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_1_3">54900000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717_510142x507364" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_4_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717_510142x507364" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_4_3">54900000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717_510142x508799" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DE01F277-AA44-4211-8026-ACEF3873B732_2_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145" unitRef="iso4217_USD" decimals="-6" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_1001_1">150000000</us-gaap:OtherCommitment>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145" unitRef="iso4217_USD" decimals="-6" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_1001_8">140000000</amrn:ChangeInControlObligations>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517065" unitRef="iso4217_USD" decimals="-5" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_3001_2">2500000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517066" unitRef="iso4217_USD" decimals="-5" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_4001_3">8000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517068" unitRef="iso4217_USD" decimals="-5" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_5001_6">13000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517069" unitRef="iso4217_USD" decimals="-5" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_6001_5">15000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517070" unitRef="iso4217_USD" decimals="-5" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_7001_4">10000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:AdditionalPercentageInterestRatePenalty contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_500478x514203" unitRef="pure" decimals="4" id="id_1522721_D7F3D695-0A55-4F6C-A147-D2AE48EF1FD1_1001_0">0.0050</amrn:AdditionalPercentageInterestRatePenalty>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_5001_500001">124597000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_5001_400001">150360933</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x502884" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_5004_700001">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_5005_800001">-747643000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_5003_600001">619266000</us-gaap:StockholdersEquity>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x513730" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_3002_10">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x513730" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_1002_1">14576000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x513730" unitRef="iso4217_USD" decimals="-6" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_3002_1">150000000</us-gaap:OtherCommitment>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x513730" unitRef="iso4217_USD" decimals="-6" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_3002_0">140000000</amrn:ChangeInControlObligations>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_1001_1">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_509379x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_0A607D97-B6A2-4FB0-992D-A514CFB44F7F_1001_0">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_511531x506189" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_1002_25">14577000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0003_STD_0_20121231_0_511531x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_F75DFFC4-2109-480E-A62E-57AFF39D57B2_2002_22">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_29_20120229_0_508454x510905" id="id_1522721_8764F3D8-5033-425D-BBA0-BDCC385B81C4_1003_1">2015-02-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0003_STD_29_20120229_0_508454x510905" unitRef="shares" decimals="INF" id="id_1522721_8764F3D8-5033-425D-BBA0-BDCC385B81C4_1003_0">584400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750" unitRef="iso4217_USD" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_1001_0">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750" unitRef="iso4217_USD" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_1001_1">62300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750" unitRef="shares" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_1001_3">66400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_1001_5">1.00</us-gaap:EquityIssuancePerShareAmount>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750" unitRef="Point" decimals="INF" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_1001_4">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750_513651x509432" unitRef="iso4217_USD" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_2001_2">3600000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750_513651x509432" unitRef="shares" decimals="-5" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_2001_9">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750_513651x509432" unitRef="Point" decimals="INF" id="id_1522721_B2AA6FDC-2974-4F7E-8E2E-A0537571255F_2001_10">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1310-Q0003_STD_31_20120131_0_500478x514203" id="id_1522721_820C70CE-6BD5-4381-BB6F-6B15E7587F36_1002_3">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1310-Q0003_STD_31_20120131_0_500478x514203" id="id_1522721_820C70CE-6BD5-4381-BB6F-6B15E7587F36_1002_2">2012-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0003_STD_31_20120131_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D10C2F85-5125-4F16-A828-FD97124C23C8_1001_3">144300000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1310-Q0003_STD_31_20120131_0_500478x514203" id="id_1522721_D10C2F85-5125-4F16-A828-FD97124C23C8_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0003_STD_31_20130131_0_499303x531046_500478x500793" unitRef="iso4217_USD" decimals="-5" id="id_1522721_059035E5-CEE0-404F-B993-1734D7C024CF_1001_0">2600000</us-gaap:InterestPaid>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_31_20130131_0_508454x510905" id="id_1522721_F38A75FE-10A4-4EF4-9658-F9AA87C94E19_1001_1">2015-08-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0003_STD_31_20130131_0_508454x510905" unitRef="shares" decimals="INF" id="id_1522721_F38A75FE-10A4-4EF4-9658-F9AA87C94E19_1001_0">434875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0" unitRef="pure" decimals="4" id="id_1522721_0A607D97-B6A2-4FB0-992D-A514CFB44F7F_1_1">0.0025</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_1522721_0A607D97-B6A2-4FB0-992D-A514CFB44F7F_1_3">0.95</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0" id="id_1522721_0A607D97-B6A2-4FB0-992D-A514CFB44F7F_1_2">P1Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_500291x672145" unitRef="iso4217_USD" decimals="-6" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_1002_0">100000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <amrn:AgreementExpirationDate contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_500291x672145" id="id_1522721_274651A0-106E-48F0-9006-03093ED40694_1002_7">2013-12-31</amrn:AgreementExpirationDate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x513639_508971x513730" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1001_3">P4Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x513639_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1001_5">0.030</amrn:FairValueInputsCouponRate>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x513639_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1001_7">0.107</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x514053_508971x513730" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2001_4">P8Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x514053_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2001_6">0.115</amrn:FairValueInputsCouponRate>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x514053_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2001_8">0.277</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <dei:TradingSymbol contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1_400000">AMRN</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1_400001">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F958DC7B-573A-40D9-9AC4-6BDB5C02893C_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1_400004">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F958DC7B-573A-40D9-9AC4-6BDB5C02893C_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F958DC7B-573A-40D9-9AC4-6BDB5C02893C_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F958DC7B-573A-40D9-9AC4-6BDB5C02893C_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F958DC7B-573A-40D9-9AC4-6BDB5C02893C_1_2">2013-03-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1_400002">0000897448</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_810066EF-9FD1-4910-BA9F-DF15683B6EE0_1_400003">--03-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_13">-7000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_34936F9D-E936-4019-A29B-8ECB9B63D33E_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Common
stock&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;During the three months
ended March&amp;#xA0;31, 2013 and March&amp;#xA0;31, 2012, the Company
issued 260,000 and 554,259 shares, respectively, as a result of the
exercise of stock options, resulting in gross and net proceeds of
$0.4 million and gross and net proceeds of $0.8 million,
respectively. In addition, during the three months ended
March&amp;#xA0;31, 2013 and March&amp;#xA0;31, 2012, the Company issued
70,000 and 40,000 shares, respectively, as a result of the exercise
of warrants, resulting in gross and net proceeds of $0.1 million
and gross and net proceeds of $0.1 million,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2013, the Company
granted 434,875 restricted stock units, or RSUs, to several
employees under the Amarin Corporation plc 2011 Stock Incentive
Plan. These RSUs vest upon the achievement of certain operational
milestones and expire on August 3, 2015 if none of the milestones
are achieved by such date. The RSUs will become fully vested upon a
change of control of the Company. Upon vesting of each RSU, the
participant shall be entitled to a payment equal to the fair market
value of one share of Amarin common stock. The payment shall be
paid to the participant in cash, or at the sole discretion of the
Compensation Committee in shares or a combination of cash or
shares. The fair value of the RSUs was determined on the date of
grant, and compensation expense related to the RSUs is recognized
once the related milestone is deemed probable. The Company recorded
no expense during the period ended March&amp;#xA0;31, 2013 related to
the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In February 2012, the
Company granted 584,400 RSUs to several employees under the Amarin
Corporation plc 2011 Stock Incentive Plan. These RSUs vest upon the
achievement of certain regulatory and time-based milestones and
expire on February&amp;#xA0;1, 2015 if none of the milestones are
achieved by such date. The RSUs will become fully vested upon a
change of control of the Company. Upon vesting of each RSU, the
participant shall be entitled to a payment equal to the fair market
value of one share of Amarin common stock. The payment shall be
paid to the participant in cash, or at the sole discretion of the
Compensation Committee in shares or a combination of cash or
shares. The fair value of the RSUs was determined on the date of
grant, and compensation expense related to the RSUs is recognized
once the related milestone is deemed probable. During the periods
ended March&amp;#xA0;31, 2013 and March&amp;#xA0;31, 2012, the Company
recorded expense of $0.1million and $0.4 million, respectively,
related to the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_6">-60051000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_20">14993000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_0">2341000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_01BFB114-F2AC-4BBB-9DC1-2CCAD8A18439_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
principally to a limited number of major wholesalers, as well as
selected regional wholesalers and specialty pharmacy providers, or
collectively, its Distributors, that in turn resell Vascepa to
retail pharmacies for subsequent resale to patients and health care
providers. Patients are required to have a prescription in order to
purchase Vascepa. The Company recognizes net product revenues from
sales of Vascepa as long as (i)&amp;#xA0;there is persuasive evidence
that an arrangement exists between the Company and the Distributor,
(ii) delivery has occurred, (iii)&amp;#xA0;collectability is reasonably
assured and (iv)&amp;#xA0;the price is fixed or
determinable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
commercial launch in the U.S on January&amp;#xA0;28, 2013. Prior to
2013, the Company recognized no revenue from Vascepa sales. Until
the Company achieves sufficient history with respect to Vascepa
sales such that it can reliably estimate returns based on sales to
its Distributors, the Company has determined that sale of product
to Distributors does not meet the criteria for revenue recognition
at the time of shipment to its Distributors due to limited returns
history which impedes the Company&amp;#x2019;s ability to estimate such
returns. Consistent with industry practice, once the Company
achieves sufficient history such that it can reliably estimate
returns based on sales to its Distributors, the Company anticipates
that its revenues will be recognized based on sales to its
Distributors. The Company currently defers Vascepa revenue
recognition until the earlier of the product being resold by the
Distributors for purposes of fulfilling patient prescriptions; or
the expiration of the right of return (twelve months after the
expiration date of the product). The Company also defers the
related cost of product sales and records such amounts as finished
goods inventory held by others until revenue related to such
product sales is recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has written
contracts with its Distributors and delivery occurs when a
Distributor receives Vascepa. The Company evaluates the
creditworthiness of each of its Distributors to determine whether
revenues can be recognized upon delivery, subject to satisfaction
of the other requirements, or whether recognition is required to be
delayed until receipt of payment. In order to conclude that the
price is fixed or determinable, the Company must be able to
(i)&amp;#xA0;calculate its gross product revenues from the sales to
Distributors and (ii)&amp;#xA0;reasonably estimate its net product
revenues. The Company calculates gross product revenues based on
the wholesale acquisition cost that the Company charges its
Distributors for Vascepa. The Company estimates its net product
revenues by deducting from its gross product revenues
(a)&amp;#xA0;trade allowances, such as invoice discounts for prompt
payment and distributor fees, (b)&amp;#xA0;estimated government and
private payor rebates, chargebacks and discounts, such as Medicaid
reimbursements, (c)&amp;#xA0;reserves for expected product returns and
(d)&amp;#xA0;estimated costs of incentives offered to certain indirect
customers, including patients.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
Vascepa sales to its Distributors for prompt payment and pays fees
for distribution services, such as fees for certain data that
Distributors provide to the Company. The payment terms for sales to
Distributors generally include a 2% discount for payment within
30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and industry
experience, the Company expects its Distributors to earn these
discounts and fees, and deducts the full amount of these discounts
and fees from its gross product revenues and accounts receivable at
the time such revenues are recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
other government agencies and various private organizations, or
collectively, its Third-party Payors, so that Vascepa will be
eligible for purchase by, or partial or full reimbursement from,
such Third-party Payors. The Company estimates the rebates,
chargebacks and discounts it will provide to Third-party Payors and
deducts these estimated amounts from its gross product revenues at
the time the revenues are recognized. The Company estimates the
rebates, chargebacks and discounts that it will provide to
Third-party Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s
contracts with these Third-party Payors, (ii)&amp;#xA0;the
government-mandated discounts applicable to government-funded
programs and (iii)&amp;#xA0;information obtained from the
Company&amp;#x2019;s Distributors and other third parties regarding the
payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
Returns:&lt;/i&gt; The Company estimates the amount of Vascepa that will
be returned and deducts these estimated amounts from its gross
revenues at the time that revenues are recognized. The
Company&amp;#x2019;s Distributors have the right to return unopened
unprescribed Vascepa during the 18-month period beginning six
months prior to the labeled expiration date and ending twelve
months after the labeled expiration date. The expiration date for
Vascepa is three years after it has been converted into capsule
form, which is the last step in the manufacturing process for
Vascepa and generally occurs within a few months before Vascepa is
delivered to Distributors. As of March&amp;#xA0;31, 2013, the Company
had not received any product returns. During the three months
ended, March&amp;#xA0;31, 2013, the first quarter in which the Company
began selling Vascepa, the Company was not able to reasonably
estimate product returns for all product sold to Distributors but
the Company was able to reasonably estimate product returns for
certain sales of Vascepa based on resale of product by its
Distributors for purposes of fulfilling patient prescriptions. In
making this assessment, the Company used (i)&amp;#xA0;data provided to
the Company by its Distributors (including weekly reporting of
Distributors&amp;#x2019; sales and inventory held by Distributors that
provided the Company with visibility into the distribution channel
in order to determine what quantities were sold to retail
pharmacies and other providers), (ii)&amp;#xA0;information provided to
the Company from retail pharmacies, (iii) data provided to the
Company by other third parties, (iv)&amp;#xA0;historical industry
information regarding return rates for similar pharmaceutical
products, (v)&amp;#xA0;the estimated remaining shelf life of Vascepa
previously shipped and currently being shipped to Distributors and
(vi)&amp;#xA0;contractual agreements intended to limit the amount of
inventory maintained by the Company&amp;#x2019;s
Distributors.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
indirect customers include co-pay mitigation rebates provided by
the Company to commercially insured patients who have coverage for
Vascepa and who reside in states that permit co-pay mitigation
programs. The Company&amp;#x2019;s co-pay mitigation program is intended
to reduce each participating patient&amp;#x2019;s portion of the
financial responsibility for Vascepa&amp;#x2019;s purchase price to a
specified dollar amount. Based upon the terms of the program and
information regarding programs provided for similar specialty
pharmaceutical products, the Company estimates the average co-pay
mitigation amounts and the percentage of patients that it expects
to participate in the program in order to establish its accruals
for co-pay mitigation rebates and deducts these estimated amounts
from its gross product revenues at the time the revenues are
recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
its accruals for co-pay mitigation rebates based on its estimates
regarding the portion of issued rebates that it estimates will not
be redeemed. In addition, as is customary prior to the launch of
new drugs, the Company provided certain of its Distributors with
financial incentives to begin stocking Vascepa prior to the
Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
that Vascepa was readily available to fill patient prescriptions
upon launch. The Company anticipates that these incentives will
only be required for initial launch quantities of Vascepa stocked
by Distributors in January 2013. The amount of these financial
incentives is recorded by the Company as a reduction to revenues on
a pro-rata basis for each of the bottles subject to such financial
incentives.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes activity in each of the product revenue allowance and
reserve categories described above for the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="63%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
Chargebacks&lt;br /&gt;
and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
January&amp;#xA0;28, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,073&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;259&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;830&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,234&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(566&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(779&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
March&amp;#xA0;31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;507&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;256&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;620&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,455&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes revenue recognized and deferred during the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue
recognized&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,341&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,865&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;5,206&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
Company&amp;#x2019;s recognition and deferral of revenues, the Company
expensed and capitalized the associated cost of goods, as follows,
during the quarter ended March 31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods
sold expensed&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,287&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods
inventory held by others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,422&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,709&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="3" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1_1">0.002</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_639EAD4A-BAC9-4A83-9FD8-373F469A1FA5_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
inventories at the lower of cost or market. Cost is determined
based on actual cost using the average cost method. An allowance is
established when management determines that certain inventories may
not be saleable. If inventory cost exceeds expected market value
due to obsolescence, damage or quantities in excess of expected
demand, the Company will record a reserve for the difference
between cost and market value. The Company received FDA approval on
July&amp;#xA0;26, 2012 and after that date began capitalizing inventory
purchases of saleable product from approved suppliers.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_8F0963E9-6F7F-4769-85C5-72DF158410B2_2_1">2017-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5005_2">2234000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_49846C8B-9018-45DA-B70D-DD265445FBDA_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three months ended
March&amp;#xA0;31, 2013 and 2012, the Company has reported its business
as a single reporting segment. The Company&amp;#x2019;s chief decision
maker, who is the Chief Executive Officer, regularly evaluates the
Company on a consolidated basis.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_9">-124000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5005_3">779000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9006_900007">4874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:DirectOperatingCosts contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_E3FF96FB-3448-4923-8F9B-1E8F7A904445_1_2">2709000</us-gaap:DirectOperatingCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9006_900004">678000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F81AFB62-4C84-4F46-B2E6-73F3A82627AA_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
consist of cash, deposits held at call with banks and short term
highly liquid instruments with remaining maturities at the date of
purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
and cash equivalents pledged to guarantee repayment of certain
expenses which may be incurred for business travel under corporate
credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_4">4874000</us-gaap:ShareBasedCompensation>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_9C65BB79-F03F-497B-ACE0-C264A4F303C8_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
of a milestone payment paid to the former shareholders of Laxdale
Limited related to the 2004 acquisition of our rights to Vascepa,
which is the result of Vascepa receiving marketing approval for the
first indication and is amortized over its estimated useful life on
a straight-line basis. The Company concluded that use of the
straight-line method was appropriate as the majority of cash flows
are expected to be generated ratably over the estimated useful life
and no degradation of the cash flows over time is currently
anticipated. See footnote 7 (commitments and contingencies) for
further information regarding other obligations related to the
acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_15">1400000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_18">3798000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_30">678000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_14">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_0">260000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_A78C90A3-631D-4C6C-B501-89480D8E72E0_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Intangible
Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
of technology rights for Vascepa and have an estimated remaining
useful life of 17.8 years. Carrying value as of March&amp;#xA0;31, 2013
and December&amp;#xA0;31, 2012 is as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
rights&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(431&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,193&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_3">59000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_27">439000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_22">-59635000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_25">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_39">563000</us-gaap:IncomeTaxesPaid>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_481DE8A0-1E99-4028-AE08-16BB0F0D7F47_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Carrying value as of
March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012 is as follows (in
thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
rights&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(431&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,193&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_24">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_3D6111F9-F6E9-41B0-8EBB-824FF4D748F4_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventories consist of the
following at March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012 (in
thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,211&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,735&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,067&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
held by others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,422&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,435&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_33">-58462000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_8DE8A675-9864-4626-8A4D-5CC463EB158D_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
liabilities are recorded at fair value, with gains and losses
arising for changes in fair value recognized in the statement of
operations at each period end while such instruments are
outstanding. If the Company issues shares to discharge the
liability, the derivative financial liability is derecognized and
common stock and additional paid-in capital are recognized on the
issuance of those shares. The warrants are valued using a
Black-Scholes option pricing model due to the nature of instrument.
The long term debt redemption feature is valued using a
probability-weighted model incorporating management estimates for
potential change in control, and by determining the fair value of
the debt with and without the change in control provision
included.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
that initially require the warrant to be classified as a derivative
financial liabilities lapse, the derivative financial liability is
reclassified out of financial liabilities into equity at its fair
value on that date. At the applicable settlement date, if the
instruments are settled in shares the carrying value of the
warrants are derecognized and transferred to equity at their fair
value at that date. The cash proceeds received from exercises of
warrants are recorded in common stock and additional paid-in
capital.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDF28B68-D96E-424E-A52C-0E4AE050C8F0_2_2">1000000</us-gaap:GainOnDerivativeInstrumentsPretax>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_EC0CE31F-4A09-4BD5-A594-2CD247DE84ED_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Subsequent
Events&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2013, the FDA
notified the Company that it accepted the Company&amp;#x2019;s ANCHOR
sNDA for review. The acceptance of the sNDA indicates that the
application is sufficiently complete to permit a substantive review
by the FDA. The application is subject to a standard review and has
been assigned a PDUFA date of December&amp;#xA0;20, 2013. The PDUFA
date is the target date for the FDA to complete its review of the
sNDA. However, there can be no assurance that the FDA will complete
its review of the sNDA by this date. In addition, in April 2013,
the FDA approved the Company&amp;#x2019;s sNDAs covering Chemport and
BASF as additional Vascepa API suppliers.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="2" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1_3">0.94</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_8">4204000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9006_900003">439000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1_2">P1Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_16">3441000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_28">70000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_10">-65415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_35D058FC-4F92-43BC-B176-EF308BBE5B88_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
value of the warrant derivative liability is as follows (in
thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="69%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;11&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
value of derivative liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;2&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="16"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;12&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,576&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,430&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,392&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,024&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;748&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,620&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;3&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;49,011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,600&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;748&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;65,359&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_4">21838000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_32">1187000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_82161D14-1AFA-44F6-A960-B8E69633EF54_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
presents information about the Company&amp;#x2019;s assets and
liabilities as of March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012
that are measured at fair value on a recurring basis and indicates
the fair value hierarchy of the valuation techniques the Company
utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
contracts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:DerivativesEmbeddedDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_EEA80BC2-46A4-40C3-B01A-C847A49FD43E_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
December 2012 financing agreement contains a redemption feature
whereby, upon a change of control, the Company would be required to
pay $140 million, less any previously repaid amount, if the change
of control occurs on or before December&amp;#xA0;31, 2013, or required
to repay $150 million, less any previously repaid amount, if the
change of control event occurs after December&amp;#xA0;31, 2013. The
Company determined this redemption feature to be an embedded
derivative, which is carried at fair value and is classified as
Level 3 in the fair value hierarchy due to the use of significant
unobservable inputs.&amp;#xA0;The fair value of the embedded derivative
was calculated using a probability-weighted model incorporating
management estimates for potential change in control, and by
determining the fair value of the debt with and without the change
in control provision included. The difference between the two fair
values of the debt was determined to be the fair value of the
embedded derivative. The fair value of the derivative liability was
calculated at both December&amp;#xA0;31, 2012 and at March&amp;#xA0;31,
2013. At December&amp;#xA0;31, 2012, the fair value of the derivative
was determined to be $14.6 million, and the debt was valued by
comparing debt issues of similar companies with (i)&amp;#xA0;terms of
between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
At March&amp;#xA0;31, 2013, the fair value of the derivative was
determined to be $15.6 million, and the debt was valued by
comparing debt issues of similar companies with (i)&amp;#xA0;remaining
terms of between 4.0 and 7.4 years, (ii)&amp;#xA0;coupon rates of
between 9.9% and 11.9% and (iii)&amp;#xA0;market yields of between
12.3% and 25.6%. The Company recognized a $1.0 million loss on
change in fair value of derivative liability at March&amp;#xA0;31,
2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DerivativesEmbeddedDerivatives>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_5D5A00DD-7F25-4F79-8B05-CA32C42FE0C3_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
liabilities are recognized for the future tax consequences of
differences between the carrying amounts and tax bases of assets
and liabilities and operating loss carry-forwards and other
attributes using enacted rates expected to be in effect when those
differences reverse. Valuation allowances are provided against
deferred tax assets that are not more likely than not to be
realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
reserves for potential payments of tax to various tax authorities
or does not recognize tax benefits related to uncertain tax
positions and other issues. Tax benefits for uncertain tax
positions are based on a determination of whether a tax benefit
taken by the Company in its tax filings or positions is more likely
than not to be realized, assuming that the matter in question will
be decided based on its technical merits. The Company&amp;#x2019;s
policy is to record interest and penalties in the provision for
income taxes.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_7">2124000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_3E5DA0CF-BC1D-4751-A868-80560AF8CFCF_1_0">4100000</us-gaap:InterestExpenseDebt>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_EBB4B20E-186A-4AFF-8AB8-8B495A513D69_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,866,826
warrants to purchase common shares outstanding at March&amp;#xA0;31,
2013 at a weighted-average exercise price of $1.44, as summarized
in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
&lt;tr&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td width="25%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
Date&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,734,888&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,866,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_5">62392000</us-gaap:OperatingExpenses>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_8">-8860000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_6">678000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_8E8430BE-97E4-4E90-A4ED-8AD59E18285D_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
initially recorded at fair value, with coupon interest and
amortization of debt issuance discounts recognized in the statement
of operations as interest expense at each period end while such
instruments are outstanding. If the Company issues shares to
discharge the liability, the debt obligation is derecognized and
common stock and additional paid-in capital are recognized on the
issuance of those shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
exchangeable notes contain a conversion option which is classified
as equity. The fair value of the liability component of the debt
instrument was deducted from the initial proceeds to determine the
proceeds to be allocated to the conversion option. The embedded
conversion option is indexed to the Company&amp;#x2019;s stock and
treated as equity on the balance sheet. The conversion option is
evaluated on a quarterly basis to determine if it still meets the
criteria to be equity classified. The excess principal amount of
the debt over the carrying value of the liability is amortized to
interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
December 2012 debt financing agreement contains a redemption
feature triggered upon a change of control, which has been
classified as an embedded derivative. The fair value of the
derivative was recorded as a reduction to the fair value of the
note payable. The fair value of this warrant derivative liability
is remeasured at each reporting period, with changes in fair value
recognized in the statement of operations. The discount recorded to
the note payable is being amortized to interest expense over the
term of the note payable.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_17">6173000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_F9DE7385-0876-4078-BA86-AD0A252BC2A1_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
research and development costs to operations as incurred. Research
and development expenses are comprised of costs incurred by the
Company in performing research and development activities,
including salary and benefits; stock-based compensation expense;
laboratory supplies and other direct expenses; contractual
services, including clinical trial and pharmaceutical development
costs; commercial supply investment in its drug candidates; and
infrastructure costs, including facilities costs and depreciation
expense. In addition, research and development costs include the
costs of product supply received from suppliers when such receipt
by the Company is prior to regulatory approval of the
supplier.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_2">1287000</us-gaap:CostOfGoodsSold>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_4BE7770E-1715-4718-9AE3-0E742C4533EE_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
general and administrative costs to operations as incurred. Sales,
general and administrative costs include costs of salaries,
programs and infrastructure necessary for the general conduct of
the Company&amp;#x2019;s business, including the 2013 commercial launch
of Vascepa in the United States for the MARINE indication. Included
as part of sales, general and administrative costs is
warrant-related expense from non-cash changes in fair value of the
derivative liability associated with warrants issued in October
2009 to former officers of Amarin which is recorded as compensation
income (expense).&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:Revenues contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_795410C5-A915-4814-8CC0-009993620A18_1_0">2341000</us-gaap:Revenues>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_DCD4EA42-C2E5-41E3-A5F0-10F45DC3E38A_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(4)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;After approval of Vascepa
on July&amp;#xA0;26, 2012 by the FDA, the Company began capitalizing
its purchases of saleable inventory of Vascepa. Inventories consist
of the following at March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012
(in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,211&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,735&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,067&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
held by others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,422&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,435&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventory is
valued at lower of cost or market, no reserve for excess or
obsolete inventory was recorded at either March 31, 2013 or
December&amp;#xA0;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_19">383000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_240B80DE-3F8B-4D28-82A2-4030FB4AA464_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(6)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long term
debt&amp;#x2014;December 2012 Financing&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On December&amp;#xA0;6, 2012,
the Company entered into an agreement with Biopharma Secured Debt
Fund II Holdings Cayman LP, or Biopharma. Under this agreement, the
Company granted to Biopharma a security interest in future
receivables associated with the Vascepa patent rights in exchange
for $100 million received at the closing of the agreement, which
closing occurred in December 2012. The Company has agreed to repay
Biopharma up to $150&amp;#xA0;million of future revenue and
receivables. The first repayment under the agreement is a repayment
of $2.5&amp;#xA0;million of interest due to be paid to Biopharma in
November 2013 for the fiscal quarter ended September&amp;#xA0;30, 2013,
subject to the limitation described below. Additional quarterly
repayments are scheduled to be paid thereafter in accordance with
the following schedule: $2.5 million of interest in the first
quarter of 2014; $8.0 million per quarter in each of the next four
quarters, $10.0 million per quarter in each of the next four
quarters, $15.0 million per quarter in each of the next four
quarters and a final payment of $13.0 million scheduled for payment
in May 2017. The quarterly repayments through the third quarter of
September 2014 represent interest only. Quarterly payments do not
begin to reduce the principal balance until the fourth quarter of
2014. These quarterly payments are subject to a quarterly threshold
amount whereby, if a calculated threshold, based on quarterly
Vascepa revenues, is not achieved, the quarterly payment payable in
that quarter can at our election be reduced, with the reduction
carried forward without interest for payment in a future period.
The payment of any carried forward amount is subject to similarly
calculated threshold repayment amounts based on Vascepa revenue
levels. Except upon a change of control in Amarin, the agreement
does not expire until $150 million has been repaid. Under the
agreement, upon a change of control, we would be required to pay
$140 million, less any previously repaid amount, if the change of
control occurs on or before December&amp;#xA0;31, 2013, or required to
repay $150 million, less any previously repaid amount, if the
change of control event occurs after December&amp;#xA0;31, 2013. The
Company can prepay after October&amp;#xA0;1, 2013, an amount equal to
$150 million less any previously repaid amount.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company determined the
redemption feature upon a change of control to be an embedded
derivative requiring bifurcation. The fair value of the embedded
derivative was calculated by determining the fair value of the debt
with the change in control provision included and also without the
change in control provision. The difference between the two fair
values of the debt was determined to be the fair value of the
embedded derivative, and the Company recorded a derivative
liability of $14.6 million as a reduction to the note payable. The
fair value of this derivative liability is remeasured at each
reporting period, with changes in fair value recognized in the
statement of operations. The fair value of the derivative liability
at March&amp;#xA0;31, 2013 was $15.6 million, and the Company
recognized a loss on change in fair value of derivative liability
of $1.0 million for the three month period ended March&amp;#xA0;31,
2013. For the three months ended March&amp;#xA0;31, 2013, the Company
recorded $3.4&amp;#xA0;million and $0.7 million of cash and non cash
interest expense, respectively. The Company will periodically
evaluate the remaining term of the agreement and the effective
interest will be recalculated each period based on the
Company&amp;#x2019;s most current estimate of repayment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company estimates that
its Vascepa revenue levels will be high enough to support repayment
to Biopharma in accordance with the repayment schedule without the
optional reduction which is allowed to be elected by the Company if
the threshold revenue levels are not achieved. Accordingly, for the
three months ended March&amp;#xA0;31, 2013, the Company recorded a
total of $4.1 million in interest expense and the Company currently
anticipates that over the scheduled repayment period it will
continue to record as interest expense the difference between the
proceeds received by the Company and the redemption amount. These
estimates will be reevaluated each reporting period by the Company
and adjusted if necessary.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2012, the Company
issued $150.0 million in principal amount of 3.5% exchangeable
senior notes due 2032, or the Notes. The Notes were issued by
Corsicanto Limited, an Irish limited company acquired by Amarin in
January 2012. Corsicanto Limited is a wholly-owned subsidiary of
Amarin. The general, unsecured, senior obligations are fully and
unconditionally guaranteed by Amarin but not by any of the
Company&amp;#x2019;s subsidiaries. Corsicanto Limited has no assets,
operations, revenues or cash flows other than those related to the
issuance, administration and repayment of the Notes.&amp;#xA0;There are
no significant restrictions on the ability of Amarin to obtain
funds from Corsicanto Limited in the form of cash dividends, loans,
or advances.&amp;#xA0;Net proceeds to the Company, after payment of
underwriting fees and expenses, were approximately $144.3
million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Notes have a stated
interest rate of 3.5%&amp;#xA0;per year, payable semiannually in
arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year beginning
on July&amp;#xA0;15, 2012, and ending upon the Notes&amp;#x2019; maturity on
January&amp;#xA0;15, 2032. The Notes are subject to repurchase by the
Company at the option of the holders on each of January&amp;#xA0;19,
2017,&amp;#xA0;January&amp;#xA0;19, 2022, and January&amp;#xA0;19, 2027, at a
price equal to 100% of the principal amount of the Notes to be
repurchased, plus accrued and unpaid interest to, but excluding,
the repurchase date. The Notes are exchangeable under certain
circumstances into cash, ADSs, or a combination of cash and ADSs,
at the Company&amp;#x2019;s election, with an initial exchange rate of
113.4752 ADSs per $1,000 principal amount of Notes. It is the
Company&amp;#x2019;s current intention to settle these obligations in
cash. If the Company elected physical settlement, the Notes would
initially be exchangeable into 17,021,280 ADSs. Based on the
closing price of the Company&amp;#x2019;s stock at March&amp;#xA0;31, 2013,
the principal amount of the Notes would exceed the value of the
shares if converted on that date by $23.9 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Additional covenants
include: (i)&amp;#xA0;limitations on future indebtedness under certain
circumstances, (ii)&amp;#xA0;the timely filing of documents and reports
pursuant to Section&amp;#xA0;13 or 15(d) of the Exchange Act with both
the SEC and the Trustee, and (iii)&amp;#xA0;maintaining the tradability
of the Notes. The Company is required to use commercially
reasonable efforts to procure and maintain the listing of the Notes
on the Global Exchange Market operated under the supervision of the
Irish Stock Exchange (or other recognized stock exchange as defined
in the Note Indenture) prior to July&amp;#xA0;15, 2012. If the Notes
are not freely tradable, as a result of restrictions pursuant to
U.S. securities law or the terms of the Indenture or the Notes, the
Company shall pay additional interest on the Notes at the rate of
0.50%&amp;#xA0;per annum of the principal amount of Notes outstanding
for each day during such period for which the Company&amp;#x2019;s
failure to file has occurred and is continuing or for which the
Notes are not freely tradable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company may not redeem
the Notes prior to January&amp;#xA0;19, 2017, other than in connection
with certain changes in the tax law of a relevant taxing
jurisdiction that results in additional amounts becoming due with
respect to payments and/or deliveries on the Notes. On or after
January&amp;#xA0;19, 2017 and prior to the maturity date, the Company
may redeem for cash all or part of the Notes at a redemption price
equal to 100% of the principal amount of the Notes to be redeemed,
plus accrued and unpaid interest to, but excluding, the redemption
date. There is no prepayment penalty or sinking fund provided for
the Notes. If the Company undergoes a fundamental change, holders
may require the Company to repurchase for cash all or part of their
Notes at a repurchase price equal to 100% of the principal amount
of the Notes to be repurchased, plus accrued and unpaid interest
to, but excluding, the fundamental change repurchase date. The
Notes are the Company&amp;#x2019;s senior unsecured obligations and rank
senior in right of payment to the Company&amp;#x2019;s future
indebtedness that is expressly subordinated in right of payment to
the Notes and equal in right of payment to the Company&amp;#x2019;s
future unsecured indebtedness that is not so subordinated. The
Notes are effectively junior in right of payment to future secured
indebtedness to the extent of the value of the assets securing such
indebtedness.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Notes are exchangeable
under certain circumstances, and the proceeds allocated to this
conversion option were determined to be $23.8 million and were
deducted from the initial fair value of the $150.0 million debt
obligation. The conversion option will not be subsequently
remeasured as long as it continues to meet conditions for equity
classification. The Company determined the fair value of the
liability component of the Notes to be $126.2 million, and the
excess of the principal amount of the liability component over the
liability is the amount allocated to the conversion option and also
results in a discount on the debt. The discount created from
allocating proceeds to the conversion option will be amortized to
interest expense using the effective interest method over the
Notes&amp;#x2019; estimated remaining life, which was calculated to be a
period of twenty-four months. The effective interest rate of the
Notes is 14.5%. As of March&amp;#xA0;31, 2013, the unamortized discount
created from the allocation of the proceeds to the conversion
option was $10.2 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company also recorded a
debt discount to reflect the value of the underwriters&amp;#x2019;
discounts and offering costs. A portion of the debt discount from
underwriter&amp;#x2019;s discounts and offering costs was allocated to
the equity and liability components of the Notes in proportion to
the proceeds allocated to each component. The portion of the debt
discount from underwriters&amp;#x2019; discounts and offering costs
allocated to the liability component is being amortized as interest
expense over the estimated remaining life of the Notes of
twenty-four months. As of March&amp;#xA0;31, 2013, the unamortized debt
discount was $2.1 million and was recorded as a direct reduction of
debt on the balance sheet. The carrying value of the Notes, net of
the unamortized discount, was $137.7 million. During the three
months ending March&amp;#xA0;31, 2013, the Company recognized interest
expense of $4.8 million related to the Notes, of which $2.9 million
represents amortization of the debt discount created upon
allocation of proceeds to the conversion option, $1.3 million
represents contractual coupon interest, and $0.6 million represents
the amortization of the discount from the underwriter&amp;#x2019;s
discounts and offering costs. At March&amp;#xA0;31, 2013, the Company
had accrued interest of $1.1 million, which has been included in
other current liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2013, the
interest payment due of $2.6 million was paid as
scheduled.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_38">2625000</us-gaap:InterestPaid>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_EDEA0C6F-7F0C-4308-A967-675E42F580FE_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Commitments and
Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Royalty
and Milestone Obligations&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company is party to
certain milestone and royalty obligations under several product
development agreements, as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The 2010 active pharmaceutical ingredient, or API, supply
agreement with the Company&amp;#x2019;s existing Japan-based supplier
provides for minimum supply purchase obligations on behalf of the
Company. As of March&amp;#xA0;31, 2013, the remaining API aggregate
minimum purchase obligations under this supply agreement were
approximately $5.4 million through 2013. The Company may purchase
more than this minimum amount.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In 2011, the Company signed agreements with two additional
suppliers for the supply of API materials for Vascepa. In 2012, the
Company agreed to terms with a fourth API supplier. These
agreements include requirements for the suppliers to qualify their
materials and facilities with applicable regulatory authorities
including the FDA. The Company anticipates incurring certain costs
associated with the qualification of product produced by these
suppliers as described below. In each case, following qualification
of the supplier for the manufacture of API for commercial sale,
these agreements include annual purchase levels to enable Amarin to
maintain exclusivity with each respective supplier, and to prevent
potential termination of the agreements. As of March&amp;#xA0;31, 2013,
these suppliers had not yet been qualified for the manufacture of
API for commercial sale and no liability was recorded for these
minimum purchase obligations. The second and third API suppliers
were approved by the FDA to manufacture API for commercial sale in
April 2013. The 2011 supply agreements include commitments for the
Company to fund (i)&amp;#xA0;development fees up to a maximum of
$0.5&amp;#xA0;million (ii)&amp;#xA0;material purchases of up to $5.0
million for initial raw materials, which amount will be credited
against future API purchases and (iii)&amp;#xA0;a raw material purchase
commitment of $1.1&amp;#xA0;million. The agreement with the fourth API
supplier, Slanmhor Pharmaceuticals, Inc., or Slanmhor, provides for
development fees of up to $2.3 million and a commitment of up to
$15.0 million, which will be credited against future API material
purchases. Under this agreement, during the three months ended
March&amp;#xA0;31, 2013, the Company made payments of $3.9 million to
Slanmhor related to stability and technical batches and advances on
future API purchases.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="2%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Under the 2004 share repurchase agreement with Laxdale Limited,
or Laxdale, upon approval of Vascepa by the FDA on July&amp;#xA0;26,
2012, the Company was required to make a milestone payment to
Laxdale of &amp;#xA3;7.5&amp;#xA0;million. The Company made this payment in
2012 and capitalized this Laxdale milestone ($11.6 million on
July&amp;#xA0;26, 2012) as a component of other long term assets. This
long-term asset is being amortized over the estimated useful life
of the intellectual property the Company acquired from Laxdale and
the Company recognized amortization expense of $0.2 million during
the three months ended March&amp;#xA0;31, 2013. Also under the Laxdale
agreement, upon receipt of marketing approval in Europe for the
first indication for Vascepa (or first indication of any product
containing Amarin Neuroscience intellectual property acquired from
Laxdale in 2004), the Company must make an aggregate stock or cash
payment to the former shareholders of Laxdale (at the sole option
of each of the sellers) of &amp;#xA3;7.5&amp;#xA0;million (approximately
$11.4 million at March&amp;#xA0;31, 2013). Also under the Laxdale
agreement, upon receipt of a marketing approval in the U.S. or
Europe for a further indication of Vascepa (or further indication
of any other product using Amarin Neuroscience intellectual
property), the Company must make an aggregate stock or cash payment
(at the sole option of each of the sellers) of &amp;#xA3;5&amp;#xA0;million
(approximately $7.6 million at March&amp;#xA0;31, 2013) for each of the
two potential market approvals (i.e. &amp;#xA3;10&amp;#xA0;million maximum,
or approximately $15.2 million at March&amp;#xA0;31, 2013).&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has no
provision for any of the obligations above since the amounts are
either not probable or estimable at March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;


&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_CA1466D7-794B-4A16-95DD-3896E4806931_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Warrants and Warrant
Derivative Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,866,826
warrants to purchase common shares outstanding at March&amp;#xA0;31,
2013 at a weighted-average exercise price of $1.44, as summarized
in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
&lt;tr&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td width="25%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td width="24%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
Date&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" nowrap="nowrap" align="center"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,734,888&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em" align="center"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,866,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;October
2009 Warrants derivative liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#xA0;16, 2009,
the Company completed a $70.0 million private placement with both
existing and new investors resulting in $62.3 million in net
proceeds and an additional $3.6 million from bridge notes converted
in conjunction with the private placement. In consideration for the
$62.3 million in net cash proceeds Amarin issued 66.4&amp;#xA0;million
units, each unit consisting of (i)&amp;#xA0;one ADS (representing one
ordinary share) at purchase price of $1.00 and (ii)&amp;#xA0;a warrant
with a five year term to purchase 0.5 of an ADS at an exercise
price of $1.50 per ADS. In consideration for the conversion of $3.6
million of convertible bridge notes, Amarin issued 4.0&amp;#xA0;million
units, each unit consisting of (i)&amp;#xA0;one ADS (representing one
ordinary share) at a purchase price of $0.90 and (ii)&amp;#xA0;a
warrant with a five year term to purchase 0.5 of an ADS an exercise
price of $1.50 per ADS. The total number of warrants issued in
conjunction with the financing was 35.2&amp;#xA0;million of which
7.5&amp;#xA0;million are outstanding at March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
October 2009 financing, the Company issued an additional
0.9&amp;#xA0;million warrants to three former officers of which
0.6&amp;#xA0;million are outstanding as of March&amp;#xA0;31, 2013. The
warrants issued in connection with the October 2009 financing
contained a pricing variability feature which provided for an
increase to the exercise price if the exchange rate between the
U.S. dollar and British pound adjusts such that the warrants could
be exercised at a price less than the &amp;#xA3;0.5 par value of the
common stock &amp;#x2013; that is, if the exchange rate exceeded U.S.
$3.00 per &amp;#xA3;1.0 sterling. Due to the potential variable nature
of the exercise price, the warrants are not considered to be
indexed to the Company&amp;#x2019;s common stock. Accordingly, the
warrants do not qualify for the exception to classify the warrants
within equity and are classified as a derivative
liability.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
warrant derivative liability is remeasured at each reporting
period, with changes in fair value recognized in the statement of
operations. Upon exercise, the fair value of the warrants exercised
is remeasured and reclassified from warrant liability to additional
paid-incapital. Although the warrants contain a pricing variability
feature, the number of warrants issuable remains fixed. Therefore,
the maximum number of common shares issuable as a result of the
October 2009 private placement is 36.1 million. The change in fair
value of the warrant derivative liability is discussed in Note
2.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;July 2009
and April 2007 Warrants&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued several
warrants in July 2009 and April 2007. As of March&amp;#xA0;31, 2013 and
December&amp;#xA0;31, 2012 these warrants have been classified as
equity instruments and have been included in the Company&amp;#x2019;s
consolidated balance sheet within additional paid-in-capital.
During the three months ended March 31, 2013, 70,000 of the July
2009 warrants were exercised, resulting in proceeds to the Company
of $0.1 million.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_11">-3949000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_12">8000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_12">-62158000</us-gaap:NetIncomeLoss>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_3">39267000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_A3A80093-FC94-47AD-86C1-1CD5D075F93B_1_0">P17Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_1485F851-14E7-46C2-A21D-69A555B403B6_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
United States dollar as the functional currency. Monetary assets
and liabilities denominated in a foreign currency are remeasured
into United States dollars at year-end exchange rates. Non-monetary
assets and liabilities carried in a foreign currency are remeasured
into United States dollars using rates of exchange prevailing when
such assets or liabilities were obtained or incurred, and expenses
are generally remeasured using rates of exchange prevailing when
such expenses are incurred. Gains and losses from the remeasurement
are included in other (expense) income, net in the consolidated
financial statements of operations. For transactions settled during
the applicable period, gains and losses are included in other
(expense) income, net in the consolidated statements of operations.
The Company uses foreign exchange forward contracts to hedge
against changes in exchange rates for inventory purchase
denominated in foreign currency. As of&amp;#xA0;March&amp;#xA0;31, 2013 the
Company held foreign exchange forward contracts with notional
amounts totaling&amp;#xA0;$15.0 million. As of&amp;#xA0;March&amp;#xA0;31,
2013, the outstanding foreign exchange forward contract derivative
liability had a net fair value of $0.7 million. The Company
included this $0.7 million as a component of change in fair value
of derivative liabilities and in Other Current Liabilities at
March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_11">-3257000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_6AC05FB0-A3DF-4938-B2E1-E21183087388_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Significant Accounting
Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
Company&amp;#x2019;s consolidated financial statements in conformity
with accounting principles generally accepted in the United States
of America, or GAAP, requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the
date of the financial statements, and the reported amounts of
revenues and expenses during the reporting period. Accounting
estimates are based on historical experience and other factors that
are considered reasonable under the circumstances. Actual results
could differ from those estimates. The preparation of the
Company&amp;#x2019;s condensed consolidated financial statements in
accordance with GAAP requires management to make estimates,
judgments and assumptions that may affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure
of contingent assets and liabilities. On an on-going basis, the
Company evaluates its estimates and judgments and methodologies,
including those related to revenue recognition and related
allowances, clinical trial expenses, the valuation of inventory,
impairment and amortization of intangibles, share-based
compensation, income taxes including the valuation allowance for
deferred tax assets, valuation of investments and derivative
instruments. The Company bases its estimates on historical
experience and on various other assumptions that are believed to be
reasonable, the results of which form the basis for making
judgments about the carrying values of assets and liabilities.
Actual results may differ from these estimates under different
assumptions or conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
principally to a limited number of major wholesalers, as well as
selected regional wholesalers and specialty pharmacy providers, or
collectively, its Distributors, that in turn resell Vascepa to
retail pharmacies for subsequent resale to patients and health care
providers. Patients are required to have a prescription in order to
purchase Vascepa. The Company recognizes net product revenues from
sales of Vascepa as long as (i)&amp;#xA0;there is persuasive evidence
that an arrangement exists between the Company and the Distributor,
(ii) delivery has occurred, (iii)&amp;#xA0;collectability is reasonably
assured and (iv)&amp;#xA0;the price is fixed or
determinable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
commercial launch in the U.S on January&amp;#xA0;28, 2013. Prior to
2013, the Company recognized no revenue from Vascepa sales. Until
the Company achieves sufficient history with respect to Vascepa
sales such that it can reliably estimate returns based on sales to
its Distributors, the Company has determined that sale of product
to Distributors does not meet the criteria for revenue recognition
at the time of shipment to its Distributors due to limited returns
history which impedes the Company&amp;#x2019;s ability to estimate such
returns. Consistent with industry practice, once the Company
achieves sufficient history such that it can reliably estimate
returns based on sales to its Distributors, the Company anticipates
that its revenues will be recognized based on sales to its
Distributors. The Company currently defers Vascepa revenue
recognition until the earlier of the product being resold by the
Distributors for purposes of fulfilling patient prescriptions; or
the expiration of the right of return (twelve months after the
expiration date of the product). The Company also defers the
related cost of product sales and records such amounts as finished
goods inventory held by others until revenue related to such
product sales is recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has written
contracts with its Distributors and delivery occurs when a
Distributor receives Vascepa. The Company evaluates the
creditworthiness of each of its Distributors to determine whether
revenues can be recognized upon delivery, subject to satisfaction
of the other requirements, or whether recognition is required to be
delayed until receipt of payment. In order to conclude that the
price is fixed or determinable, the Company must be able to
(i)&amp;#xA0;calculate its gross product revenues from the sales to
Distributors and (ii)&amp;#xA0;reasonably estimate its net product
revenues. The Company calculates gross product revenues based on
the wholesale acquisition cost that the Company charges its
Distributors for Vascepa. The Company estimates its net product
revenues by deducting from its gross product revenues
(a)&amp;#xA0;trade allowances, such as invoice discounts for prompt
payment and distributor fees, (b)&amp;#xA0;estimated government and
private payor rebates, chargebacks and discounts, such as Medicaid
reimbursements, (c)&amp;#xA0;reserves for expected product returns and
(d)&amp;#xA0;estimated costs of incentives offered to certain indirect
customers, including patients.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
Vascepa sales to its Distributors for prompt payment and pays fees
for distribution services, such as fees for certain data that
Distributors provide to the Company. The payment terms for sales to
Distributors generally include a 2% discount for payment within
30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and industry
experience, the Company expects its Distributors to earn these
discounts and fees, and deducts the full amount of these discounts
and fees from its gross product revenues and accounts receivable at
the time such revenues are recognized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
other government agencies and various private organizations, or
collectively, its Third-party Payors, so that Vascepa will be
eligible for purchase by, or partial or full reimbursement from,
such Third-party Payors. The Company estimates the rebates,
chargebacks and discounts it will provide to Third-party Payors and
deducts these estimated amounts from its gross product revenues at
the time the revenues are recognized. The Company estimates the
rebates, chargebacks and discounts that it will provide to
Third-party Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s
contracts with these Third-party Payors, (ii)&amp;#xA0;the
government-mandated discounts applicable to government-funded
programs and (iii)&amp;#xA0;information obtained from the
Company&amp;#x2019;s Distributors and other third parties regarding the
payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
Returns:&lt;/i&gt; The Company estimates the amount of Vascepa that will
be returned and deducts these estimated amounts from its gross
revenues at the time that revenues are recognized. The
Company&amp;#x2019;s Distributors have the right to return unopened
unprescribed Vascepa during the 18-month period beginning six
months prior to the labeled expiration date and ending twelve
months after the labeled expiration date. The expiration date for
Vascepa is three years after it has been converted into capsule
form, which is the last step in the manufacturing process for
Vascepa and generally occurs within a few months before Vascepa is
delivered to Distributors. As of March&amp;#xA0;31, 2013, the Company
had not received any product returns. During the three months
ended, March&amp;#xA0;31, 2013, the first quarter in which the Company
began selling Vascepa, the Company was not able to reasonably
estimate product returns for all product sold to Distributors but
the Company was able to reasonably estimate product returns for
certain sales of Vascepa based on resale of product by its
Distributors for purposes of fulfilling patient prescriptions. In
making this assessment, the Company used (i)&amp;#xA0;data provided to
the Company by its Distributors (including weekly reporting of
Distributors&amp;#x2019; sales and inventory held by Distributors that
provided the Company with visibility into the distribution channel
in order to determine what quantities were sold to retail
pharmacies and other providers), (ii)&amp;#xA0;information provided to
the Company from retail pharmacies, (iii) data provided to the
Company by other third parties, (iv)&amp;#xA0;historical industry
information regarding return rates for similar pharmaceutical
products, (v)&amp;#xA0;the estimated remaining shelf life of Vascepa
previously shipped and currently being shipped to Distributors and
(vi)&amp;#xA0;contractual agreements intended to limit the amount of
inventory maintained by the Company&amp;#x2019;s
Distributors.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
indirect customers include co-pay mitigation rebates provided by
the Company to commercially insured patients who have coverage for
Vascepa and who reside in states that permit co-pay mitigation
programs. The Company&amp;#x2019;s co-pay mitigation program is intended
to reduce each participating patient&amp;#x2019;s portion of the
financial responsibility for Vascepa&amp;#x2019;s purchase price to a
specified dollar amount. Based upon the terms of the program and
information regarding programs provided for similar specialty
pharmaceutical products, the Company estimates the average co-pay
mitigation amounts and the percentage of patients that it expects
to participate in the program in order to establish its accruals
for co-pay mitigation rebates and deducts these estimated amounts
from its gross product revenues at the time the revenues are
recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
its accruals for co-pay mitigation rebates based on its estimates
regarding the portion of issued rebates that it estimates will not
be redeemed. In addition, as is customary prior to the launch of
new drugs, the Company provided certain of its Distributors with
financial incentives to begin stocking Vascepa prior to the
Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
that Vascepa was readily available to fill patient prescriptions
upon launch. The Company anticipates that these incentives will
only be required for initial launch quantities of Vascepa stocked
by Distributors in January 2013. The amount of these financial
incentives is recorded by the Company as a reduction to revenues on
a pro-rata basis for each of the bottles subject to such financial
incentives.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes activity in each of the product revenue allowance and
reserve categories described above for the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="63%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
Chargebacks&lt;br /&gt;
and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
January&amp;#xA0;28, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,073&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;259&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;830&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,234&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(566&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(779&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
March&amp;#xA0;31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;507&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;256&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;620&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,455&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes revenue recognized and deferred during the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue
recognized&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,341&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,865&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;5,206&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
Company&amp;#x2019;s recognition and deferral of revenues, the Company
expensed and capitalized the associated cost of goods, as follows,
during the quarter ended March 31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods
sold expensed&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,287&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods
inventory held by others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,422&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,709&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
consist of cash, deposits held at call with banks and short term
highly liquid instruments with remaining maturities at the date of
purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
and cash equivalents pledged to guarantee repayment of certain
expenses which may be incurred for business travel under corporate
credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
inventories at the lower of cost or market. Cost is determined
based on actual cost using the average cost method. An allowance is
established when management determines that certain inventories may
not be saleable. If inventory cost exceeds expected market value
due to obsolescence, damage or quantities in excess of expected
demand, the Company will record a reserve for the difference
between cost and market value. The Company received FDA approval on
July&amp;#xA0;26, 2012 and after that date began capitalizing inventory
purchases of saleable product from approved suppliers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
of a milestone payment paid to the former shareholders of Laxdale
Limited related to the 2004 acquisition of our rights to Vascepa,
which is the result of Vascepa receiving marketing approval for the
first indication and is amortized over its estimated useful life on
a straight-line basis. The Company concluded that use of the
straight-line method was appropriate as the majority of cash flows
are expected to be generated ratably over the estimated useful life
and no degradation of the cash flows over time is currently
anticipated. See footnote 7 (commitments and contingencies) for
further information regarding other obligations related to the
acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
product shipments to Distributors for which we have invoiced the
Distributors but not recognized revenue because the product was not
reported to us as having been resold by the Distributors on or
before March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
research and development costs to operations as incurred. Research
and development expenses are comprised of costs incurred by the
Company in performing research and development activities,
including salary and benefits; stock-based compensation expense;
laboratory supplies and other direct expenses; contractual
services, including clinical trial and pharmaceutical development
costs; commercial supply investment in its drug candidates; and
infrastructure costs, including facilities costs and depreciation
expense. In addition, research and development costs include the
costs of product supply received from suppliers when such receipt
by the Company is prior to regulatory approval of the
supplier.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
general and administrative costs to operations as incurred. Sales,
general and administrative costs include costs of salaries,
programs and infrastructure necessary for the general conduct of
the Company&amp;#x2019;s business, including the 2013 commercial launch
of Vascepa in the United States for the MARINE indication. Included
as part of sales, general and administrative costs is
warrant-related expense from non-cash changes in fair value of the
derivative liability associated with warrants issued in October
2009 to former officers of Amarin which is recorded as compensation
income (expense).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
liabilities are recognized for the future tax consequences of
differences between the carrying amounts and tax bases of assets
and liabilities and operating loss carry-forwards and other
attributes using enacted rates expected to be in effect when those
differences reverse. Valuation allowances are provided against
deferred tax assets that are not more likely than not to be
realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
reserves for potential payments of tax to various tax authorities
or does not recognize tax benefits related to uncertain tax
positions and other issues. Tax benefits for uncertain tax
positions are based on a determination of whether a tax benefit
taken by the Company in its tax filings or positions is more likely
than not to be realized, assuming that the matter in question will
be decided based on its technical merits. The Company&amp;#x2019;s
policy is to record interest and penalties in the provision for
income taxes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
liabilities are recorded at fair value, with gains and losses
arising for changes in fair value recognized in the statement of
operations at each period end while such instruments are
outstanding. If the Company issues shares to discharge the
liability, the derivative financial liability is derecognized and
common stock and additional paid-in capital are recognized on the
issuance of those shares. The warrants are valued using a
Black-Scholes option pricing model due to the nature of instrument.
The long term debt redemption feature is valued using a
probability-weighted model incorporating management estimates for
potential change in control, and by determining the fair value of
the debt with and without the change in control provision
included.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
that initially require the warrant to be classified as a derivative
financial liabilities lapse, the derivative financial liability is
reclassified out of financial liabilities into equity at its fair
value on that date. At the applicable settlement date, if the
instruments are settled in shares the carrying value of the
warrants are derecognized and transferred to equity at their fair
value at that date. The cash proceeds received from exercises of
warrants are recorded in common stock and additional paid-in
capital.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
determined by dividing net loss by the weighted average shares of
common stock outstanding during the period. Diluted net loss per
share is determined by dividing net loss by diluted weighted
average shares outstanding. Diluted weighted average shares
reflects the dilutive effect, if any, of potentially dilutive
common shares, such as common stock options and warrants calculated
using the treasury stock method and convertible notes using the
&amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
operating losses, all common stock options and warrants are deemed
anti-dilutive such that basic net loss per share and diluted net
loss per share are equal.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
initially recorded at fair value, with coupon interest and
amortization of debt issuance discounts recognized in the statement
of operations as interest expense at each period end while such
instruments are outstanding. If the Company issues shares to
discharge the liability, the debt obligation is derecognized and
common stock and additional paid-in capital are recognized on the
issuance of those shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
exchangeable notes contain a conversion option which is classified
as equity. The fair value of the liability component of the debt
instrument was deducted from the initial proceeds to determine the
proceeds to be allocated to the conversion option. The embedded
conversion option is indexed to the Company&amp;#x2019;s stock and
treated as equity on the balance sheet. The conversion option is
evaluated on a quarterly basis to determine if it still meets the
criteria to be equity classified. The excess principal amount of
the debt over the carrying value of the liability is amortized to
interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
December 2012 debt financing agreement contains a redemption
feature triggered upon a change of control, which has been
classified as an embedded derivative. The fair value of the
derivative was recorded as a reduction to the fair value of the
note payable. The fair value of this warrant derivative liability
is remeasured at each reporting period, with changes in fair value
recognized in the statement of operations. The discount recorded to
the note payable is being amortized to interest expense over the
term of the note payable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
disclosure of financial assets and financial liabilities that are
carried at fair value based on the price that would be received
upon sale of an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement
date.&amp;#xA0;Fair value measurements may be classified based on the
amount of subjectivity associated with the inputs to fair valuation
of these assets and liabilities using the following three
levels:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the
measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
include quoted prices for similar assets and liabilities in active
markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, inputs other than
quoted prices that are observable for the asset or liability (i.e.,
interest rates, yield curves, etc.) and inputs that are derived
principally from or corroborated by observable market data by
correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
inputs that reflect the Company&amp;#x2019;s estimates of the
assumptions that market participants would use in pricing the asset
or liability.&amp;#xA0;The Company develops these inputs based on the
best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
presents information about the Company&amp;#x2019;s assets and
liabilities as of March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012
that are measured at fair value on a recurring basis and indicates
the fair value hierarchy of the valuation techniques the Company
utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
contracts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
cash, cash equivalents, accounts payable and accrued liabilities
approximate fair value because of their short-term
nature.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
the fair value of the warrant derivative liability was determined
to be $54.9 million using the Black-Scholes option valuation model
applying the following assumptions: (i)&amp;#xA0;risk-free rate of
0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At March&amp;#xA0;31, 2013, the
fair value of the warrant derivative liability was determined to be
$49.0 million using the Black-Scholes option valuation model
applying the following assumptions: (i)&amp;#xA0;risk-free rate of
0.2%, (ii)&amp;#xA0;remaining term of 1.5 years, (iii)&amp;#xA0;no dividend
yield, (iv)&amp;#xA0;volatility of 94%, and (v)&amp;#xA0;the stock price on
the date of measurement.&amp;#xA0;The $5.9 million decrease in the fair
value of the warrant liability during the three months ended
March&amp;#xA0;31, 2013 was recognized as: (i)&amp;#xA0;a $5.4 million gain
on change in fair value of the remaining derivative liability and
(ii)&amp;#xA0;$0.5 million in compensation income for change in fair
value of warrants issued to former employees. Both amounts are
included in the consolidated statement of operations for the three
months ended March&amp;#xA0;31, 2013.&amp;#xA0;The change in the fair value
of the warrant derivative liability is as follows (in
thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="69%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;11&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
value of derivative liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;2&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="16"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;12&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,576&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,430&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,392&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,024&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;748&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,620&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;3&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;49,011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,600&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;748&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;65,359&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
warrant liability is determined using the Black-Scholes option
valuation model and is therefore sensitive to changes in the market
price and volatility of our common stock among other
factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
market price of our common shares ($8.15 based on the $7.41 market
price of our stock at March&amp;#xA0;28, 2013) on which the
March&amp;#xA0;31, 2013 valuation was based, the value of the
derivative liability would have increased by
$5.9&amp;#xA0;million.&amp;#xA0;Such increase would have been reflected as
additional loss on change in fair value of the warrant derivative
liability in our statement of operations. Significant increases
(decreases) in this input in isolation would result in a
significantly higher (lower) fair value asset
measurement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
December 2012 financing agreement contains a redemption feature
whereby, upon a change of control, the Company would be required to
pay $140 million, less any previously repaid amount, if the change
of control occurs on or before December&amp;#xA0;31, 2013, or required
to repay $150 million, less any previously repaid amount, if the
change of control event occurs after December&amp;#xA0;31, 2013. The
Company determined this redemption feature to be an embedded
derivative, which is carried at fair value and is classified as
Level 3 in the fair value hierarchy due to the use of significant
unobservable inputs.&amp;#xA0;The fair value of the embedded derivative
was calculated using a probability-weighted model incorporating
management estimates for potential change in control, and by
determining the fair value of the debt with and without the change
in control provision included. The difference between the two fair
values of the debt was determined to be the fair value of the
embedded derivative. The fair value of the derivative liability was
calculated at both December&amp;#xA0;31, 2012 and at March&amp;#xA0;31,
2013. At December&amp;#xA0;31, 2012, the fair value of the derivative
was determined to be $14.6 million, and the debt was valued by
comparing debt issues of similar companies with (i)&amp;#xA0;terms of
between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
At March&amp;#xA0;31, 2013, the fair value of the derivative was
determined to be $15.6 million, and the debt was valued by
comparing debt issues of similar companies with (i)&amp;#xA0;remaining
terms of between 4.0 and 7.4 years, (ii)&amp;#xA0;coupon rates of
between 9.9% and 11.9% and (iii)&amp;#xA0;market yields of between
12.3% and 25.6%. The Company recognized a $1.0 million loss on
change in fair value of derivative liability at March&amp;#xA0;31,
2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
United States dollar as the functional currency. Monetary assets
and liabilities denominated in a foreign currency are remeasured
into United States dollars at year-end exchange rates. Non-monetary
assets and liabilities carried in a foreign currency are remeasured
into United States dollars using rates of exchange prevailing when
such assets or liabilities were obtained or incurred, and expenses
are generally remeasured using rates of exchange prevailing when
such expenses are incurred. Gains and losses from the remeasurement
are included in other (expense) income, net in the consolidated
financial statements of operations. For transactions settled during
the applicable period, gains and losses are included in other
(expense) income, net in the consolidated statements of operations.
The Company uses foreign exchange forward contracts to hedge
against changes in exchange rates for inventory purchase
denominated in foreign currency. As of&amp;#xA0;March&amp;#xA0;31, 2013 the
Company held foreign exchange forward contracts with notional
amounts totaling&amp;#xA0;$15.0 million. As of&amp;#xA0;March&amp;#xA0;31,
2013, the outstanding foreign exchange forward contract derivative
liability had a net fair value of $0.7 million. The Company
included this $0.7 million as a component of change in fair value
of derivative liabilities and in Other Current Liabilities at
March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three months ended
March&amp;#xA0;31, 2013 and 2012, the Company has reported its business
as a single reporting segment. The Company&amp;#x2019;s chief decision
maker, who is the Chief Executive Officer, regularly evaluates the
Company on a consolidated basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
accounting pronouncements are issued by the Financial Accounting
Standards Board, or FASB, and are adopted by the Company as of the
specified effective date. The Company believes that the impact of
other recently issued but not yet adopted accounting pronouncements
will not have a material impact on consolidated financial position,
results of operations, and cash flows, or do not apply to the
Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_9C40E94B-8A54-46F8-8F31-9AC222827B4F_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
Company&amp;#x2019;s consolidated financial statements in conformity
with accounting principles generally accepted in the United States
of America, or GAAP, requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the
date of the financial statements, and the reported amounts of
revenues and expenses during the reporting period. Accounting
estimates are based on historical experience and other factors that
are considered reasonable under the circumstances. Actual results
could differ from those estimates. The preparation of the
Company&amp;#x2019;s condensed consolidated financial statements in
accordance with GAAP requires management to make estimates,
judgments and assumptions that may affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure
of contingent assets and liabilities. On an on-going basis, the
Company evaluates its estimates and judgments and methodologies,
including those related to revenue recognition and related
allowances, clinical trial expenses, the valuation of inventory,
impairment and amortization of intangibles, share-based
compensation, income taxes including the valuation allowance for
deferred tax assets, valuation of investments and derivative
instruments. The Company bases its estimates on historical
experience and on various other assumptions that are believed to be
reasonable, the results of which form the basis for making
judgments about the carrying values of assets and liabilities.
Actual results may differ from these estimates under different
assumptions or conditions.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_6579DCE7-FF4E-447F-B11E-4598BD02A3B8_1_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Nature of Business and
Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Nature
of Business&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin Corporation plc,
&amp;#x201C;Amarin&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;, is a public
limited company with its primary stock market listing in the United
States on the NASDAQ Global Market. Amarin was originally
incorporated in England as a private limited company on
March&amp;#xA0;1, 1989 under the Companies Act 1985, and re-registered
in England as a public limited company on March&amp;#xA0;19,
1993.&lt;/font&gt;&lt;/p&gt;
&lt;p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is a
biopharmaceutical company with expertise in lipid science focused
on the commercialization and development of therapeutics to improve
cardiovascular health. On July&amp;#xA0;26, 2012, the Company received
approval from the U.S. Food and Drug Administration , or FDA, to
market and sell its lead product Vascepa&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
(icosapent ethyl) capsules (formerly known as AMR 101) as an
adjunct to diet to reduce triglyceride levels in adult patients
with severe (TG &lt;u&gt;&amp;gt;&lt;/u&gt;500mg/dL) hypertriglyceridemia, which
the Company sometimes refers to as the MARINE indication.
Triglycerides are fats in the blood. Vascepa became commercially
available in the United States by prescription in January 2013,
when the Company commenced sales and shipments to its network of
U.S.-based wholesalers and specialty pharmacy providers. On
January&amp;#xA0;28, 2013, the Company commenced its full commercial
launch of Vascepa in the United States for use in the MARINE
indication.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is also developing
Vascepa for the treatment of patients with high triglyceride levels
(TG &lt;u&gt;&amp;gt;&lt;/u&gt;200 mg/dL and &amp;lt;500 mg/dL) who are also on statin
therapy for elevated LDL-C levels. This indication is referred to
as mixed dyslipidemia or the ANCHOR indication. In February 2013,
the Company submitted a supplemental New Drug Application, or sNDA,
to the FDA seeking approval of Vascepa for the ANCHOR indication.
In April 2013, the FDA notified the Company that it accepted the
ANCHOR sNDA for review. The acceptance of the ANCHOR sNDA for
review indicates that the application is sufficiently complete to
permit a substantive review by the FDA. The application is subject
to a standard review and has been assigned a Prescription Drug User
Fee Act, or PDUFA, date of December&amp;#xA0;20, 2013. The PDUFA date
is the target date for the FDA to complete its review of the sNDA.
However, there can be no assurance that the FDA will complete its
review of the sNDA by this date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Basis
of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The condensed consolidated
financial statements included herein have been prepared by the
Company, without audit, in accordance with accounting principles
generally accepted in the United States of America (the
&amp;#x201C;U.S.&amp;#x201D; or the &amp;#x201C;United States&amp;#x201D;) and pursuant
to the rules and regulations of the Securities and Exchange
Commission (the &amp;#x201C;SEC&amp;#x201D;). Certain information in the
footnote disclosures of the financial statements has been condensed
or omitted where it substantially duplicates information provided
in the Company&amp;#x2019;s latest audited consolidated financial
statements, in accordance with the rules and regulations of the
SEC. These condensed consolidated financial statements should be
read in conjunction with the Company&amp;#x2019;s audited consolidated
financial statements and notes included in its Annual Report on
Form 10-K for the fiscal year ended December 31, 2012, filed with
the SEC (the &amp;#x201C;2012 Form 10-K&amp;#x201D;). The balance sheet
amounts at December 31, 2012 in this report were derived from the
Company&amp;#x2019;s audited 2012 consolidated financial statements
included in the 2012 Form 10-K. The condensed consolidated
financial statements reflect all adjustments that, in the opinion
of management, are necessary to present fairly the Company&amp;#x2019;s
financial position, results of operations and cash flows for the
periods indicated. The preparation of financial statements in
conformity with U.S. Generally Accepted Accounting Principles
(&amp;#x201C;GAAP&amp;#x201D;) requires management to make estimates and
assumptions that affect the reported amounts and classifications of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period. The results of operations for the three months ended March
31, 2013 and March 31, 2012, respectively, are not necessarily
indicative of the results for the entire fiscal year or any future
period. The Company has evaluated subsequent events from March 31,
2013 through the date of the issuance of these condensed
consolidated financial statements and has disclosed subsequent
events in Note 9.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying
consolidated financial statements of the Company and subsidiaries
have been prepared on a basis which assumes that the Company will
continue as a going concern, which contemplates the realization of
assets and the satisfaction of liabilities and commitments in the
normal course of business. Prior to 2004, the Company was in the
business of selling a previous biopharmaceutical compound, which
has since been discontinued. The Company&amp;#x2019;s current focus is
on the commercialization and development of Vascepa, which received
approval from the FDA in 2012 and for which the Company commenced
marketing and sales in 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At March&amp;#xA0;31, 2013, the
Company had cash and cash equivalents of $201.8&amp;#xA0;million. The
Company&amp;#x2019;s consolidated balance sheet also includes derivative
liabilities (see footnote 5&amp;#x2014;Warrants and Derivative
Liabilities) as well as long term debt and exchangeable senior
notes (see footnote 6&amp;#x2014;Debt). The warrant derivative liability
reflects the fair value of outstanding warrants to purchase shares
of the Company&amp;#x2019;s common stock. This liability can only be
settled in shares of the Company&amp;#x2019;s stock and, as such, would
only result in cash inflows upon the exercise of the
warrants&amp;#x2014;not a cash out-flow. The long term debt is not
callable except upon a change in control. The Exchangeable Senior
Notes may be redeemed on or after January&amp;#xA0;19, 2017 at the
option of the holders. The Notes are exchangeable under certain
circumstances into cash, American Depository Shares, or ADSs, or a
combination of cash and ADSs, at the Company&amp;#x2019;s election.
Accordingly, the warrant derivative liability, long term debt and
Exchangeable Senior Notes do not present a short term claim on the
liquid assets of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes its
cash and cash equivalents will be sufficient to fund its projected
operations for at least the next twelve months, including the
continued commercialization of Vascepa and the advancement of the
REDUCE-IT cardiovascular outcomes study. In order to fund the
Company&amp;#x2019;s commercialization plans, in particular to fully
support the marketing and sale of Vascepa in the ANCHOR indication,
the Company will likely need to enter into a strategic
collaboration or raise additional capital.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_86B78789-F1FE-4656-92BF-612705F07DB6_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
determined by dividing net loss by the weighted average shares of
common stock outstanding during the period. Diluted net loss per
share is determined by dividing net loss by diluted weighted
average shares outstanding. Diluted weighted average shares
reflects the dilutive effect, if any, of potentially dilutive
common shares, such as common stock options and warrants calculated
using the treasury stock method and convertible notes using the
&amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
operating losses, all common stock options and warrants are deemed
anti-dilutive such that basic net loss per share and diluted net
loss per share are equal.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_9">161000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_6E53625C-768A-425F-A9B7-19E25FAB39DE_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
disclosure of financial assets and financial liabilities that are
carried at fair value based on the price that would be received
upon sale of an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement
date.&amp;#xA0;Fair value measurements may be classified based on the
amount of subjectivity associated with the inputs to fair valuation
of these assets and liabilities using the following three
levels:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the
measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
include quoted prices for similar assets and liabilities in active
markets, quoted prices for identical or similar assets or
liabilities in markets that are not active, inputs other than
quoted prices that are observable for the asset or liability (i.e.,
interest rates, yield curves, etc.) and inputs that are derived
principally from or corroborated by observable market data by
correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
inputs that reflect the Company&amp;#x2019;s estimates of the
assumptions that market participants would use in pricing the asset
or liability.&amp;#xA0;The Company develops these inputs based on the
best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
presents information about the Company&amp;#x2019;s assets and
liabilities as of March&amp;#xA0;31, 2013 and December&amp;#xA0;31, 2012
that are measured at fair value on a recurring basis and indicates
the fair value hierarchy of the valuation techniques the Company
utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
contracts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long term debt redemption
feature&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
cash, cash equivalents, accounts payable and accrued liabilities
approximate fair value because of their short-term
nature.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_7">3620000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9006_900002">70000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1_41">0</amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9006_900006">8000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:ProductSales contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_795410C5-A915-4814-8CC0-009993620A18_1_2">5206000</amrn:ProductSales>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_1">400000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_4">100000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_3">70000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:CashDiscountInvoiceTerms contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_0A132215-A454-4BF7-95CB-40C51624E25E_1_1">P30D</amrn:CashDiscountInvoiceTerms>
  <amrn:RecentAccountingPronouncementsPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_92BDA301-287A-4272-B60B-47A4585F4CD0_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
accounting pronouncements are issued by the Financial Accounting
Standards Board, or FASB, and are adopted by the Company as of the
specified effective date. The Company believes that the impact of
other recently issued but not yet adopted accounting pronouncements
will not have a material impact on consolidated financial position,
results of operations, and cash flows, or do not apply to the
Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</amrn:RecentAccountingPronouncementsPolicyTextBlock>
  <amrn:DeferredRevenuePolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_4436BD05-BA0D-4F45-A060-2842B299F45E_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
product shipments to Distributors for which we have invoiced the
Distributors but not recognized revenue because the product was not
reported to us as having been resold by the Distributors on or
before March&amp;#xA0;31, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</amrn:DeferredRevenuePolicyTextBlock>
  <amrn:ScheduleOfCostOfRevenueTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_E20759AA-58BC-4B9F-B156-F9EC3855A7CD_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
Company&amp;#x2019;s recognition and deferral of revenues, the Company
expensed and capitalized the associated cost of goods, as follows,
during the quarter ended March 31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods
sold expensed&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,287&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: -1em; MARGIN-BOTTOM: 1px; MARGIN-LEFT: 1em"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods
inventory held by others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,422&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,709&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</amrn:ScheduleOfCostOfRevenueTableTextBlock>
  <amrn:SignificantAssumptionsInMarketPriceOfStock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="pure" decimals="2" id="id_1522721_645AB998-988C-4445-BAD6-69B812D2EED2_1_3">0.10</amrn:SignificantAssumptionsInMarketPriceOfStock>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_5">100000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:SummaryOfValuationAllowancesTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_AD44F94D-F349-4275-B291-0DFE6D00342C_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes activity in each of the product revenue allowance and
reserve categories described above for the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="63%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
Chargebacks&lt;br /&gt;
and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
January&amp;#xA0;28, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,073&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;259&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;830&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,234&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
current period and deferred sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(566&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(779&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
March&amp;#xA0;31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;507&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;256&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;620&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,455&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</amrn:SummaryOfValuationAllowancesTableTextBlock>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_1_2">400000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" unitRef="shares" decimals="0" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_1_16">150430</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <amrn:RevenuesTableTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0" id="id_1522721_399478D3-07B6-420C-ADFB-01BD6777A61C_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
summarizes revenue recognized and deferred during the quarter ended
March&amp;#xA0;31, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue
recognized&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,341&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,865&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;5,206&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</amrn:RevenuesTableTextBlock>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_497966x530903_508971x512835" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDE90AE0-565D-4FD5-AFE1-8303D769F646_1001_2">700000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_498752x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1001_5">-451000</us-gaap:ShareBasedCompensation>
  <us-gaap:DebtInstrumentConvertibleEffectiveInterestRate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" unitRef="pure" decimals="3" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_1001_3">0.145</us-gaap:DebtInstrumentConvertibleEffectiveInterestRate>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_1001_4">1300000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_1001_0">P24M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_1001_3">4800000</us-gaap:InterestExpenseDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_1001_5">2900000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_1001_0">23800000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <amrn:DebtInstrumentMaturityPeriod contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203" id="id_1522721_7C027007-148C-4B68-808B-3189F6F0A3B3_1001_2">P24M</amrn:DebtInstrumentMaturityPeriod>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203_507189x534687" unitRef="iso4217_USD" decimals="-5" id="id_1522721_EE0E3D78-421D-4097-83EB-F5068852D9E7_2001_6">600000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203_513696x536012" unitRef="shares" decimals="INF" id="id_1522721_820C70CE-6BD5-4381-BB6F-6B15E7587F36_2001_1">17021280</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203_513696x536012" unitRef="pure" decimals="4" id="id_1522721_820C70CE-6BD5-4381-BB6F-6B15E7587F36_2001_0">113.4752</us-gaap:DebtInstrumentConvertibleConversionRatio>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_6004_2">-3620000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x511672" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_6003_2">748000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x513730" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_6002_2">1024000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_6001_2">-5392000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_503939x507958" id="id_1522721_B52F6EFF-EFF3-4EFA-BCC1-E579B09F7DAD_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
the fair value of the warrant derivative liability was determined
to be $54.9 million using the Black-Scholes option valuation model
applying the following assumptions: (i)&amp;#xA0;risk-free rate of
0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At March&amp;#xA0;31, 2013, the
fair value of the warrant derivative liability was determined to be
$49.0 million using the Black-Scholes option valuation model
applying the following assumptions: (i)&amp;#xA0;risk-free rate of
0.2%, (ii)&amp;#xA0;remaining term of 1.5 years, (iii)&amp;#xA0;no dividend
yield, (iv)&amp;#xA0;volatility of 94%, and (v)&amp;#xA0;the stock price on
the date of measurement.&amp;#xA0;The $5.9 million decrease in the fair
value of the warrant liability during the three months ended
March&amp;#xA0;31, 2013 was recognized as: (i)&amp;#xA0;a $5.4 million gain
on change in fair value of the remaining derivative liability and
(ii)&amp;#xA0;$0.5 million in compensation income for change in fair
value of warrants issued to former employees. Both amounts are
included in the consolidated statement of operations for the three
months ended March&amp;#xA0;31, 2013.&amp;#xA0;The change in the fair value
of the warrant derivative liability is as follows (in
thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="69%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;11&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
value of derivative liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;66,209&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,374&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(321&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;2&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;191,387&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="16"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;td height="16" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;br /&gt;
2009&lt;br /&gt;
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;br /&gt;
Redemption&lt;br /&gt;
Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;br /&gt;
Exchange&lt;br /&gt;
Contracts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 20&lt;/b&gt;&lt;b&gt;12&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,576&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,430&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,392&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,024&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;748&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,620&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
change in fair value of warrants issued to former
employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(451&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
equity&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at&lt;/b&gt;
&lt;b&gt;March&lt;/b&gt;&lt;b&gt;&amp;#xA0;31, 201&lt;/b&gt;&lt;b&gt;3&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;49,011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,600&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;748&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;65,359&lt;/b&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
warrant liability is determined using the Black-Scholes option
valuation model and is therefore sensitive to changes in the market
price and volatility of our common stock among other
factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
market price of our common shares ($8.15 based on the $7.41 market
price of our stock at March&amp;#xA0;28, 2013) on which the
March&amp;#xA0;31, 2013 valuation was based, the value of the
derivative liability would have increased by
$5.9&amp;#xA0;million.&amp;#xA0;Such increase would have been reflected as
additional loss on change in fair value of the warrant derivative
liability in our statement of operations. Significant increases
(decreases) in this input in isolation would result in a
significantly higher (lower) fair value asset
measurement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x513639_508971x513730" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1003_11">P4Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x513639_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1003_13">0.099</amrn:FairValueInputsCouponRate>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x513639_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_1003_15">0.123</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:MaturityPeriodUsedToClassifyInvestments contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053" id="id_1522721_A8918BA5-F3E2-4874-9AC9-D1D8805BB8D1_1001_0">P90D</amrn:MaturityPeriodUsedToClassifyInvestments>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_508971x513730" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2003_12">P7Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2003_14">0.119</amrn:FairValueInputsCouponRate>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_508971x513730" unitRef="pure" decimals="3" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_2003_16">0.256</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537757" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_1001_5">15000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537757" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_1001_4">2300000</amrn:DevelopmentFeesCommitted>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537848" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_2001_2">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537848" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_2001_1">500000</amrn:DevelopmentFeesCommitted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_400003">260000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_500003">196000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_500002">52000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_500006">1000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_400002">70000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348" unitRef="shares" decimals="0" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9001_400005">948</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9005_800008">-62158000</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9003_600007">4874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9003_600004">678000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9003_600003">243000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9003_600002">18000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_9003_600006">7000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x502651" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5003_2">72000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x509157" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5001_2">1073000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x509157" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5001_3">566000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x586139" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5002_2">259000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x586139" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5002_3">3000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x589068" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5004_2">830000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x589068" unitRef="iso4217_USD" decimals="-3" id="id_1522721_7C336E83-E409-4ED8-AA5D-CE7B4CF2E31C_5004_3">209000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x501039" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDF28B68-D96E-424E-A52C-0E4AE050C8F0_1002_3">3400000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x517783" unitRef="iso4217_USD" decimals="-5" id="id_1522721_645AB998-988C-4445-BAD6-69B812D2EED2_1001_2">5900000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x534240" unitRef="iso4217_USD" decimals="-5" id="id_1522721_BDF28B68-D96E-424E-A52C-0E4AE050C8F0_2002_4">700000</us-gaap:InterestExpense>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_508454x510905" unitRef="iso4217_USD" decimals="-5" id="id_1522721_8764F3D8-5033-425D-BBA0-BDCC385B81C4_1001_2">100000</us-gaap:RestrictedStockExpense>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_508971x513730" unitRef="iso4217_USD" decimals="-5" id="id_1522721_DB3523A6-83B2-458E-A638-95E0BA0F889D_3003_9">1000000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_508971x517760_510508x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_7001_3">451000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760" unitRef="iso4217_USD" decimals="-5" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1001_6">500000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760" unitRef="iso4217_USD" decimals="-5" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1001_4">-5900000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760" unitRef="iso4217_USD" decimals="-5" id="id_1522721_46F3608A-7720-474D-899C-787A7406E3D9_1001_5">5400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:EmbeddedDerivativeDescriptionOfHostContract contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760_512768x517750" id="id_1522721_7672B5B2-089A-4A59-9CCF-ACA22860E609_1001_0">The warrants issued in connection with the October 2009 financing contained apricing variability feature which provided for an increase to the exercise priceif the exchange rate between the U.S. dollar and British pound adjusts such thatthe warrants could be exercised at a price less than the 0.5 par value of thecommon stock - that is, if the exchange rate exceeded U.S. $3.00 per 1.0sterling. Due to the potential variable nature of the exercise price, thewarrants are not considered to be indexed to the Company&apos;s common stock.Accordingly, the warrants do not qualify for the exception to classify thewarrants within equity and are classified as a derivative liability.</us-gaap:EmbeddedDerivativeDescriptionOfHostContract>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517767" unitRef="iso4217_USD" decimals="-5" id="id_1522721_59474221-629D-488C-8F70-A1E29231A7D5_1001_1">100000</us-gaap:ProceedsFromWarrantExercises>
  <amrn:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517767" unitRef="shares" decimals="INF" id="id_1522721_59474221-629D-488C-8F70-A1E29231A7D5_1001_0">70000</amrn:ClassOfWarrantOrRightExercisedInPeriod>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_510508x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_71316BB2-82A1-4EF8-B661-80B39712263A_7004_3">451000</us-gaap:ShareBasedCompensation>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x536635" unitRef="iso4217_USD" decimals="-5" id="id_1522721_7BCAE181-D5F8-4489-8156-B51A81103F29_1003_3">200000</us-gaap:AdjustmentForAmortization>
  <us-gaap:PaymentsForPurchaseOfOtherAssets contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x537260" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_3001_6">3900000</us-gaap:PaymentsForPurchaseOfOtherAssets>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x537848" unitRef="iso4217_USD" decimals="-5" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_4001_3">1100000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:NumberOfAgreements contextRef="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x537848" unitRef="Contract" decimals="0" id="id_1522721_D38B4CDB-62F3-4171-9426-7FEBBCF4A68A_4001_0">2</amrn:NumberOfAgreements>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_13">-8000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_6">-18783000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_20">1137000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_9">68000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900018">3874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900015">1884000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_4">3874000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_18">3131000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_21">2793000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_30">1884000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_14">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="INF" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_0">554259</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_3">32000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_27">791000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_22">-17737000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_25">-92000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_39">111000</us-gaap:IncomeTaxesPaid>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_24">92000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_33">129220000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900014">791000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_28">59000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_10">-88875000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_4">4756000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_32">147049000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900013">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_7">1196000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_5">18783000</us-gaap:OperatingExpenses>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_8">-3951000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_6">1884000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900012">321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_19">2050000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_31">1000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_12">6000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_12">-88285000</us-gaap:NetIncomeLoss>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_3">14027000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_29">144316000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_11">-590000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_7">-66209000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900011">59000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_2_41">321000</amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4006_900017">6000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_1">800000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_4">100000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="INF" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_3">40000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_5004_4">321000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_5">100000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-5" id="id_1522721_5EAE600F-7F0F-4549-BD03-4DD0B25454CD_2_2">800000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0" unitRef="shares" decimals="0" id="id_1522721_6C996CA3-E9C7-4E47-8F22-70FF06F8F066_2_16">136011</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_498752x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_BFDF2387-F2FD-415F-856D-7C48F7D53E1F_1002_5">2374000</us-gaap:ShareBasedCompensation>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_503845x566640" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_6004_2">66209000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_503845x566640_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_6001_2">66209000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4001_400014">554249</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4001_500014">438000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4001_500011">31000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348" unitRef="shares" decimals="INF" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4001_400011">40000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348" unitRef="shares" decimals="0" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4001_400016">894</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x503287" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4005_800019">-88285000</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600018">3874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600015">1884000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600014">353000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600013">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600012">321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600011">28000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619" unitRef="iso4217_USD" decimals="-3" id="id_1522721_372F254D-380C-4A16-BB2A-361058DF69DD_4003_600017">6000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_508454x510905" unitRef="iso4217_USD" decimals="-5" id="id_1522721_8764F3D8-5033-425D-BBA0-BDCC385B81C4_1002_2">400000</us-gaap:RestrictedStockExpense>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_508971x517760" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_5001_4">321000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_508971x517760_510508x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_7001_3">-2374000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0003_STD_91_20120331_0_510508x507958" unitRef="iso4217_USD" decimals="-3" id="id_1522721_D5006480-AB84-4DA3-A6EC-C7B0517999AD_7004_3">-2374000</us-gaap:ShareBasedCompensation>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_510508x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_508971x517760_510508x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_508454x510905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_503845x566640_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_503845x566640">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0_498752x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_91_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x537848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x537260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_530648x536635">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_510508x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517767">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedJulyTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_509379x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_508971x517760_510508x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_508454x510905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x534240">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x517783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_507189x501039">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x589068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x586139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x509157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_506932x502651">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_530648x537757">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x514053">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_504957x513639_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_503939x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640_508971x511672">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_503845x566640">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203_513696x536012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203_507189x534687">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:DebtOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_500478x514203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_498752x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0_497966x530903_508971x512835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amrn:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x514053_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_366_20121231_0_504957x513639_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_366_20121231_0_500291x672145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_31_20130131_0_508454x510905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_31_20130131_0_499303x531046_500478x500793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_31_20120131_0_500478x514203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750_513651x509432">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_31_20091031_0_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_29_20120229_0_508454x510905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_511531x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_511531x506189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_509379x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x502884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500478x514203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517070">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517069">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517066">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145_530598x517065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_500291x672145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717_510142x508799">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717_510142x507364">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0_498503x502717">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x502884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_511531x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_511531x506189">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_509379x517760_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_509379x507958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x513730">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x512835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_508971x511672">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_507611x504721_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517787">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517789_530648x536635_530651x517786">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517787">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_507189x517788_530648x536635_530651x517786">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x589068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x586139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x509157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_506932x502651">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x502884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_504957x514053_509379x517760_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_504957x514053_507189x517789_530648x536635">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517822">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517821">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_503939x517820">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203_507189x531855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ProceedsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_500478x514203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x508799">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717_510142x507364">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0_498503x502717">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0_508971x517760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x508619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x503287">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x502884">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0_505872x501348">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20091016_0_512768x517750_513651x509432">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750_513651x509432">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20091016_0_509379x517760_510508x530899_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20091016_0_507611x504721_512768x517750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120726_0_530648x536635">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-26</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130328_0_507189x517783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-28</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130328_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2013-03-28</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130502_0_513696x536012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-02</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20130502_0_513696x531187">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-02</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120131_0_500478x514203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0003_STD_0_20120131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>amrn:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="Point">
    <measure>amrn:Point</measure>
  </unit>
  <unit id="Contract">
    <measure>amrn:Contract</measure>
  </unit>
</xbrl>